{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T03:38:36Z","timestamp":1772768316935,"version":"3.50.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100009780","name":"Region Sk\u00e5ne","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009780","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Lund University Hospital"},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det (SE)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004817","name":"Lund University Medical Faculty Foundation (SE)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004817","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005390","name":"Alfred \u00d6sterlunds Stiftelse (SE)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005390","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006075","name":"Greta och Johan Kock Stiftelse (SE)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006075","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007949","name":"Swedish Rheumatism Association","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007949","id-type":"DOI","asserted-by":"crossref"}]},{"name":"King Gustav V 80-year fund"},{"DOI":"10.13039\/100001275","name":"Oak Foundation (US)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001275","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s13075-015-0897-6","type":"journal-article","created":{"date-parts":[[2015,12,24]],"date-time":"2015-12-24T09:09:27Z","timestamp":1450948167000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Comparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients \u2013 baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4915-2924","authenticated-orcid":false,"given":"Johan K.","family":"Wallman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meliha C.","family":"Kapetanovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingemar F.","family":"Petersson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Geborek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars Erik","family":"Kristensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,12,24]]},"reference":[{"key":"897_CR1","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S Linden van der","year":"1984","unstructured":"van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361\u20138.","journal-title":"Arthritis Rheum"},{"key":"897_CR2","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/art.24483","volume":"60","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, Haibel H, Baraliakos X, Listing J, Marker-Hermann E, Zeidler H, et al. The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum. 2009;60:717\u201327.","journal-title":"Arthritis Rheum."},{"key":"897_CR3","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akkoc N, Brandt J, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68:777\u201383.","journal-title":"Ann Rheum Dis."},{"key":"897_CR4","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/acr.21688","volume":"64","author":"U Kiltz","year":"2012","unstructured":"Kiltz U, Baraliakos X, Karakostas P, Igelmann M, Kalthoff L, Klink C, et al. Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis? Arthritis Care Res (Hoboken). 2012;64:1415\u201322.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"897_CR5","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1002\/art.38140","volume":"65","author":"A Ciurea","year":"2013","unstructured":"Ciurea A, Scherer A, Exer P, Bernhard J, Dudler J, Beyeler B, et al. Tumor necrosis factor alpha inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort. Arthritis Rheum. 2013;65:3096\u2013106.","journal-title":"Arthritis Rheum."},{"key":"897_CR6","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/rheumatology\/ket164","volume":"52","author":"R Berg van den","year":"2013","unstructured":"van den Berg R, de Hooge M, van Gaalen F, Reijnierse M, Huizinga T, van der Heijde D. Percentage of patients with spondyloarthritis in patients referred because of chronic back pain and performance of classification criteria: experience from the Spondyloarthritis Caught Early (SPACE) cohort. Rheumatology (Oxford). 2013;52:1492\u20139.","journal-title":"Rheumatology (Oxford)"},{"key":"897_CR7","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.3899\/jrheum.130588","volume":"40","author":"D Wallis","year":"2013","unstructured":"Wallis D, Haroon N, Ayearst R, Carty A, Inman RD. Ankylosing spondylitis and nonradiographic axial spondyloarthritis: part of a common spectrum or distinct diseases? J Rheumatol. 2013;40:2038\u201341.","journal-title":"J Rheumatol."},{"key":"897_CR8","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1093\/rheumatology\/ket207","volume":"52","author":"M Blachier","year":"2013","unstructured":"Blachier M, Canoui-Poitrine F, Dougados M, Lethuaut A, Fautrel B, Ferkal S, et al. Factors associated with radiographic lesions in early axial spondyloarthritis. Results from the DESIR cohort. Rheumatology (Oxford). 2013;52:1686\u201393.","journal-title":"Rheumatology (Oxford)"},{"key":"897_CR9","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/BOR.0000000000000071","volume":"26","author":"D Poddubnyy","year":"2014","unstructured":"Poddubnyy D, Sieper J. Similarities and differences between nonradiographic and radiographic axial spondyloarthritis: a clinical, epidemiological and therapeutic assessment. Curr Opin Rheumatol. 2014;26:377\u201383.","journal-title":"Curr Opin Rheumatol."},{"key":"897_CR10","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.semarthrit.2014.10.009","volume":"44","author":"A Boonen","year":"2015","unstructured":"Boonen A, Sieper J, van der Heijde D, Dougados M, Bukowski JF, Valluri S, et al. The burden of non-radiographic axial spondyloarthritis. Semin Arthritis Rheum. 2015;44:556\u201362.","journal-title":"Semin Arthritis Rheum."},{"key":"897_CR11","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1136\/ard.2010.145995","volume":"70","author":"D Poddubnyy","year":"2011","unstructured":"Poddubnyy D, Rudwaleit M, Haibel H, Listing J, Marker-Hermann E, Zeidler H, et al. Rates and predictors of radiographic sacroiliitis progression over 2\u00a0years in patients with axial spondyloarthritis. Ann Rheum Dis. 2011;70:1369\u201374.","journal-title":"Ann Rheum Dis."},{"key":"897_CR12","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1136\/ard.2011.151563","volume":"70","author":"D Heijde van der","year":"2011","unstructured":"van der Heijde D, Sieper J, Maksymowych WP, Dougados M, Burgos-Vargas R, Landewe R, et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis. 2011;70:905\u20138.","journal-title":"Ann Rheum Dis."},{"key":"897_CR13","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/ard.2011.151027","volume":"70","author":"J Braun","year":"2011","unstructured":"Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E, et al. 2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011;70:896\u2013904.","journal-title":"Ann Rheum Dis."},{"key":"897_CR14","unstructured":"Svensk Reumatologisk F\u00f6rening. Riktlinjer f\u00f6r l\u00e4kemedelsbehandling vid ankyloserande spondylit och psoriasisartrit (mars-2015). http:\/\/svenskreumatologi.se\/sites\/default \/files\/Riktlinjer_AS_PsoA_2015.pdf. Accessed 9 Nov 2015."},{"key":"897_CR15","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/annrheumdis-2012-202389","volume":"72","author":"IH Song","year":"2013","unstructured":"Song IH, Weiss A, Hermann KG, Haibel H, Althoff CE, Poddubnyy D, et al. Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1\u00a0year of treatment with etanercept: results from the ESTHER trial. Ann Rheum Dis. 2013;72:823\u20135.","journal-title":"Ann Rheum Dis."},{"key":"897_CR16","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/art.38973","volume":"67","author":"J Sieper","year":"2015","unstructured":"Sieper J, Landewe R, Rudwaleit M, van der Heijde D, Dougados M, Mease PJ, et al. Effect of Certolizumab Pegol Over Ninety-Six Weeks in Patients With Axial Spondyloarthritis: Results from a Phase III Randomized Trial. Arthritis Rheumatol. 2015;67:668\u201377.","journal-title":"Arthritis Rheumatol."},{"key":"897_CR17","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1136\/ard.61.9.793","volume":"61","author":"P Geborek","year":"2002","unstructured":"Geborek P, Crnkic M, Petersson IF, Saxne T. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis. 2002;61:793\u20138.","journal-title":"Ann Rheum Dis."},{"key":"897_CR18","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/rheumatology\/ker169","volume":"51","author":"LE Kristensen","year":"2012","unstructured":"Kristensen LE, Petersson IF, Geborek P, Joud A, Saxne T, Jacobsson LT, et al. Sick leave in patients with ankylosing spondylitis before and after anti-TNF therapy: a population-based cohort study. Rheumatology (Oxford). 2012;51:243\u20139.","journal-title":"Rheumatology (Oxford)"},{"key":"897_CR19","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1136\/ard.2005.040758","volume":"65","author":"J Braun","year":"2006","unstructured":"Braun J, Davis J, Dougados M, Sieper J, van der Linden S, van der Heijde D, et al. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis. 2006;65:316\u201320.","journal-title":"Ann Rheum Dis."},{"key":"897_CR20","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0168-8510(96)00822-6","volume":"37","author":"R Brooks","year":"1996","unstructured":"Brooks R. EuroQol: the current state of play. Health Policy. 1996;37:53\u201372.","journal-title":"Health Policy."},{"key":"897_CR21","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","volume":"35","author":"P Dolan","year":"1997","unstructured":"Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35:1095\u2013108.","journal-title":"Med Care."},{"key":"897_CR22","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21:2286\u201391.","journal-title":"J Rheumatol."},{"key":"897_CR23","first-page":"2281","volume":"21","author":"A Calin","year":"1994","unstructured":"Calin A, Garrett S, Whitelock H, Kennedy LG, O\u2019Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994;21:2281\u20135.","journal-title":"J Rheumatol."},{"key":"897_CR24","first-page":"789","volume":"9","author":"JF Fries","year":"1982","unstructured":"Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol. 1982;9:789\u201393.","journal-title":"J Rheumatol."},{"key":"897_CR25","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","volume":"73","author":"R Landewe","year":"2014","unstructured":"Landewe R, Braun J, Deodhar A, Dougados M, Maksymowych WP, Mease PJ, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis. 2014;73:39\u201347.","journal-title":"Ann Rheum Dis."},{"key":"897_CR26","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1136\/annrheumdis-2014-205322","volume":"74","author":"J Callhoff","year":"2015","unstructured":"Callhoff J, Sieper J, Weiss A, Zink A, Listing J. Efficacy of TNFalpha blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. Ann Rheum Dis. 2015;74:1241\u20138.","journal-title":"Ann Rheum Dis."},{"key":"897_CR27","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","volume":"359","author":"J Braun","year":"2002","unstructured":"Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002;359:1187\u201393.","journal-title":"Lancet."},{"key":"897_CR28","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1002\/art.11325","volume":"48","author":"JC Davis Jr","year":"2003","unstructured":"Davis Jr JC, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 2003;48:3230\u20136.","journal-title":"Arthritis Rheum."},{"key":"897_CR29","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","volume":"54","author":"D Heijde van der","year":"2006","unstructured":"van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54:2136\u201346.","journal-title":"Arthritis Rheum."},{"key":"897_CR30","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1002\/art.23606","volume":"58","author":"H Haibel","year":"2008","unstructured":"Haibel H, Rudwaleit M, Listing J, Heldmann F, Wong RL, Kupper H, et al. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum. 2008;58:1981\u201391.","journal-title":"Arthritis Rheum."},{"key":"897_CR31","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2012-201766","volume":"72","author":"J Sieper","year":"2013","unstructured":"Sieper J, van der Heijde D, Dougados M, Mease PJ, Maksymowych WP, Brown MA, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis. 2013;72:815\u201322.","journal-title":"Ann Rheum Dis."},{"key":"897_CR32","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/art.38721","volume":"66","author":"M Dougados","year":"2014","unstructured":"Dougados M, van der Heijde D, Sieper J, Braun J, Maksymowych WP, Citera G, et al. Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2014;66:2091\u2013102.","journal-title":"Arthritis Rheumatol."},{"key":"897_CR33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta11280","volume":"11","author":"C McLeod","year":"2007","unstructured":"McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, et al. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. Health Technol Assess. 2007;11:1\u2013158. iii-iv.","journal-title":"Health Technol Assess"},{"key":"897_CR34","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.3899\/jrheum.140056","volume":"41","author":"IH Song","year":"2014","unstructured":"Song IH, Hermann KG, Haibel H, Althoff CE, Poddubnyy D, Listing J, et al. Consistently Good clinical response in patients with early axial spondyloarthritis after 3\u00a0years of continuous treatment with etanercept: longterm data of the ESTHER trial. J Rheumatol. 2014;41:2034\u201340.","journal-title":"J Rheumatol."},{"key":"897_CR35","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/art.24408","volume":"60","author":"N Barkham","year":"2009","unstructured":"Barkham N, Keen HI, Coates LC, O\u2019Connor P, Hensor E, Fraser AD, et al. Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum. 2009;60:946\u201354.","journal-title":"Arthritis Rheum."},{"key":"897_CR36","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1136\/ard.2003.016386","volume":"63","author":"M Rudwaleit","year":"2004","unstructured":"Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis. 2004;63:665\u201370.","journal-title":"Ann Rheum Dis."},{"key":"897_CR37","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/ard.2003.006916","volume":"63","author":"MA Stone","year":"2004","unstructured":"Stone MA, Payne U, Pacheco-Tena C, Inman RD. Cytokine correlates of clinical response patterns to infliximab treatment of ankylosing spondylitis. Ann Rheum Dis. 2004;63:84\u20137.","journal-title":"Ann Rheum Dis."},{"key":"897_CR38","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1136\/ard.2007.073098","volume":"67","author":"M Rudwaleit","year":"2008","unstructured":"Rudwaleit M, Schwarzlose S, Hilgert ES, Listing J, Braun J, Sieper J. MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. Ann Rheum Dis. 2008;67:1276\u201381.","journal-title":"Ann Rheum Dis."},{"key":"897_CR39","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3899\/jrheum.081048","volume":"36","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, Claudepierre P, Wordsworth P, Cortina EL, Sieper J, Kron M, et al. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol. 2009;36:801\u20138.","journal-title":"J Rheumatol."},{"key":"897_CR40","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/rheumatology\/kep422","volume":"49","author":"PA Lord","year":"2010","unstructured":"Lord PA, Farragher TM, Lunt M, Watson KD, Symmons DP, Hyrich KL, et al. Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). 2010;49:563\u201370.","journal-title":"Rheumatology (Oxford)"},{"key":"897_CR41","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1136\/ard.2010.147744","volume":"70","author":"N Vastesaeger","year":"2011","unstructured":"Vastesaeger N, van der Heijde D, Inman RD, Wang Y, Deodhar A, Hsu B, et al. Predicting the outcome of ankylosing spondylitis therapy. Ann Rheum Dis. 2011;70:973\u201381.","journal-title":"Ann Rheum Dis."},{"key":"897_CR42","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3109\/03009742.2014.918173","volume":"43","author":"A Gulfe","year":"2014","unstructured":"Gulfe A, Kapetanovic MC, Kristensen LE. Efficacy and drug survival of anti-tumour necrosis factor-alpha therapies in patients with non-radiographic axial spondyloarthritis: an observational cohort study from Southern Sweden. Scand J Rheumatol. 2014;43:493\u20137.","journal-title":"Scand J Rheumatol."},{"key":"897_CR43","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1002\/acr.20258","volume":"62","author":"LE Kristensen","year":"2010","unstructured":"Kristensen LE, Karlsson JA, Englund M, Petersson IF, Saxne T, Geborek P. Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register. Arthritis Care Res (Hoboken). 2010;62:1362\u20139.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"897_CR44","first-page":"2078","volume":"34","author":"M Luc","year":"2007","unstructured":"Luc M, Gossec L, Ruyssen-Witrand A, Salliot C, Duclos M, Guignard S, et al. C-reactive protein predicts tumor necrosis factor-alpha blocker retention rate in axial ankylosing spondylitis. J Rheumatol. 2007;34:2078\u201381.","journal-title":"J Rheumatol."},{"key":"897_CR45","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1002\/acr.22001","volume":"65","author":"A Tournadre","year":"2013","unstructured":"Tournadre A, Pereira B, Lhoste A, Dubost JJ, Ristori JM, Claudepierre P, et al. Differences between women and men with recent-onset axial spondyloarthritis: results from a prospective multicenter French cohort. Arthritis Care Res (Hoboken). 2013;65:1482\u20139.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"897_CR46","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3899\/jrheum.130959","volume":"42","author":"J Braun","year":"2015","unstructured":"Braun J, Baraliakos X, Kiltz U, Heldmann F, Sieper J. Classification and diagnosis of axial spondyloarthritis--what is the clinically relevant difference? J Rheumatol. 2015;42:31\u20138.","journal-title":"J Rheumatol."},{"issue":"Suppl 2","key":"897_CR47","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1136\/annrheumdis-2015-eular.5965","volume":"74","author":"X Baraliakos","year":"2015","unstructured":"Baraliakos X, Regel A, Kiltz U, Kiefer D, Menne H-J, Dybowski F, et al. Patients with fibromyalgia (FM) do not fulfill classification criteria for axial spondyloarthritis (axSpA) but patients with axSpA may fulfill classification criteria for FM. Ann Rheum Dis. 2015;74 Suppl 2:80. doi: 10.1136\/annrheumdis-2015-eular.5965 .","journal-title":"Ann Rheum Dis"},{"key":"897_CR48","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00296-014-2955-9","volume":"34","author":"F Salaffi","year":"2014","unstructured":"Salaffi F, De Angelis R, Carotti M, Gutierrez M, Sarzi-Puttini P, Atzeni F. Fibromyalgia in patients with axial spondyloarthritis: epidemiological profile and effect on measures of disease activity. Rheumatol Int. 2014;34:1103\u201310.","journal-title":"Rheumatol Int."},{"key":"897_CR49","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1007\/s00296-014-2972-8","volume":"34","author":"S Haliloglu","year":"2014","unstructured":"Haliloglu S, Carlioglu A, Akdeniz D, Karaaslan Y, Kosar A. Fibromyalgia in patients with other rheumatic diseases: prevalence and relationship with disease activity. Rheumatol Int. 2014;34:1275\u201380.","journal-title":"Rheumatol Int."},{"issue":"Suppl 2","key":"897_CR50","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1136\/annrheumdis-2015-eular.2831","volume":"74","author":"N Bello Vega","year":"2015","unstructured":"Bello Vega N, B\u00e9al C, Etcheto A, Dougados M, Molto A. How fibromyalgia impacts clinical and treatment aspects in spondyloarthritis patients: results of the Fispa study. Ann Rheum Dis. 2015;74 Suppl 2:506\u20137. doi: 10.1136\/annrheumdis-2015-eular.2831 .","journal-title":"Ann Rheum Dis."},{"key":"897_CR51","unstructured":"U.S. Food and Drug Administration. Arthritis advisory committee meeting July 23, 2013. sBLA 125057\/323: adalimumab for the treatment of Active non-radiographic axial spondyloarthritis in adults with objective signs of inflammation by elevated c-reactive protein (CRP) or magnetic resonance imaging (MRI), who have had an inadequate response to, or are intolerant to, a nonsteroidal anti-inflammatory drug. http:\/\/www.fda.gov\/downloads\/ AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/ArthritisAdvisoryCommittee\/UCM361563.pdf. Accessed 21 Nov 2015."}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-015-0897-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T22:51:08Z","timestamp":1748731868000},"score":1,"resource":{"primary":{"URL":"http:\/\/arthritis-research.com\/content\/17\/1\/378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["897"],"URL":"https:\/\/doi.org\/10.1186\/s13075-015-0897-6","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12]]},"article-number":"378"}}